The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy and safety of first-line cetuximab + FOLFIRI in older and younger patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the CRYSTAL study.
 
Eric Van Cutsem
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst)
 
Claus-Henning Köhne
Honoraria - Amgen; Bayer; Merck; Pfizer; Sanofi
 
Gunnar Folprecht
Honoraria - Bayer; Lilly/ImClone; Merck KGaA
Consulting or Advisory Role - Bristol-Myers Squibb; Lilly/ImClone; Merck KGaA; Roche/Genentech
Research Funding - Merck KGaA
 
Silke Guenther
Employment - Merck KGaA
 
Frank Beier
Employment - Merck KGaA
 
Demetris Papamichael
Consulting or Advisory Role - Amgen; Merck; Roche
Speakers' Bureau - Amgen; Merck; Roche
Travel, Accommodations, Expenses - Amgen; MSD